DrugPatentWatch Database Preview
Sb Pharmco Company Profile
What is the competitive landscape for SB PHARMCO, and what generic alternatives to SB PHARMCO drugs are available?
SB PHARMCO has three approved drugs.
There are two US patents protecting SB PHARMCO drugs.
Summary for Sb Pharmco
| US Patents: | 2 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Sb Pharmco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sb Pharmco | AVANDIA | rosiglitazone maleate | TABLET;ORAL | 021071-002 | May 25, 1999 | RX | Yes | No | 7,358,366*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Sb Pharmco | AVANDAMET | metformin hydrochloride; rosiglitazone maleate | TABLET;ORAL | 021410-005 | Aug 25, 2003 | DISCN | Yes | No | 8,236,345 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Sb Pharmco | AVANDIA | rosiglitazone maleate | TABLET;ORAL | 021071-003 | May 25, 1999 | RX | Yes | No | 7,358,366*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Sb Pharmco | AVANDARYL | glimepiride; rosiglitazone maleate | TABLET;ORAL | 021700-001 | Nov 23, 2005 | DISCN | Yes | No | 7,358,366*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Sb Pharmco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sb Pharmco | AVANDAMET | metformin hydrochloride; rosiglitazone maleate | TABLET;ORAL | 021410-002 | Oct 10, 2002 | 5,741,803*PED | ➤ Sign Up |
| Sb Pharmco | AVANDAMET | metformin hydrochloride; rosiglitazone maleate | TABLET;ORAL | 021410-003 | Oct 10, 2002 | 6,166,042*PED | ➤ Sign Up |
| Sb Pharmco | AVANDAMET | metformin hydrochloride; rosiglitazone maleate | TABLET;ORAL | 021410-002 | Oct 10, 2002 | 5,965,584*PED | ➤ Sign Up |
| Sb Pharmco | AVANDIA | rosiglitazone maleate | TABLET;ORAL | 021071-002 | May 25, 1999 | 6,288,095*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for SB PHARMCO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 1 mg/4 mg, 2 mg/4 mg and 4 mg/4 mg | ➤ Subscribe | 2006-12-22 |
| ➤ Subscribe | Tablets | 1 mg/ 500 mg, 2 mg/ 500mg, 4 mg/ 500 mg, 2 mg/ 1000 mg and 4 mg/ 1000 mg | ➤ Subscribe | 2004-10-22 |
| ➤ Subscribe | Tablets | 8 mg/2 mg and 8 mg/4 mg | ➤ Subscribe | 2008-05-30 |
International Patents for Sb Pharmco Drugs
Supplementary Protection Certificates for Sb Pharmco Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0677 | Netherlands | ➤ Sign Up | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 |
| 00357 | Netherlands | ➤ Sign Up | PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 |
| 1730131/02 | Switzerland | ➤ Sign Up | PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015 |
| 2014026 | Lithuania | ➤ Sign Up | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
